Skip to main content
. 2017 Dec 28;18:86–96. doi: 10.1016/j.nicl.2017.12.032

Table 2.

Summary of neuropsychological evaluation.

C + (n = 17) C– (n = 15) HC (n = 18) p-Value
Cognitive impairmentc 5 (29%) 3 (20%) 1 (6%) 0.18
Mattis dementia rating scale-2a 144 (133–144) 144 (140–144) 144 (139–144) 0.91
BDI (≥ 13)c 5 (29) 4 (27) 2 (11) 0.30
Estimated verbal IQ
 WAIS-III vocabulary sub-test 0 ± 1.03 0.21 ± 0.73 1.05 ± 1.13 0.01
Language
 Brief Spanish adaptation of the Boston naming test 0.33 ± 0.86 0.25 ± 0.59 0.56 ± 0.68 0.59
Verbal fluency
 Semantic fluency 0.43 ± 0.70 0.28 ± 0.65 0.30 ± 0.76 0.67
 Phonemic fluency − 0.33 ± 1.23 − 0.23 ± 1.12 0.5 ± 0.72 0.05
Processing speed/executive functions
 Trail Making test A (TMT-A) − 0.45 ± 0.87 − 0.08 ± 0.72 0.31 ± 0.97 0.06
 Trail Making test B (TMT-B) − 0.83 ± 0.82 − 0.41 ± 0.99 − 0.02 ± 0.75 0.04
 TMT-B minus TMT-A (in seconds)a 144 ± 96 112 ± 118 66 ± 45 0.02
Attention/working memory
 WAIS-III digits sub-test 0.15 ± 1.12 0.28 ± 0.57 0.65 ± 0.80 0.20
Visuospatial abilities
 ROCF first copy 0.60 ± 1.05 1.23 ± 1.24 1.68 ± 1.03 0.03
Visual memory
 ROCF delayed 0.43 ± 0.80 1 ± 0.97 0.78 ± 0.73 0.26
Verbal memorya
 AVLT immediate recall (A1) 4.06 ± 2.01 3.43 ± 1.28⁎⁎ 5.06 ± 1.62 0.03
 AVLT immediate recall (B) 4.50 ± 0.85 4.86 ± 1.77 5 ± 1.37 0.60
 AVLT short-delay recall(A6) 5.86 ± 1.61 6.71 ± 3.45 7.72 ± 3.23 0.23
 AVLT long-delay recall(A7) 5.38 ± 2.55 6.21 ± 3.11 7.39 ± 3.52 0.29

All results are z-scores mean ± SD except for araw score, bmedian (range), cn (%).

C +: chemotherapy-treated small-cell lung cancer group; C −: non-chemotherapy treated non-small cell lung cancer group; HC: healthy control group; BDI: Beck Depression Inventory test, IQ: intelligence quotient, WAIS-III: Wechsler Adult Intelligence Scale-III, ROCF: Rey-Osterrieth Complex Figure, AVLT: Auditory Verbal Learning Test.

Statistically significant results are marked in bold.

Significant differences were between C + and HC.

⁎⁎

Significant differences were between C– and HC.